Compounds > alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
Page last updated: 2024-10-21

alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Basal Ganglia Diseases

alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid has been researched along with Basal Ganglia Diseases in 1 studies

alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.

Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Johnson, AE1
Liminga, U1
Lidén, A1
Lindefors, N1
Gunne, LM1
Wiesel, FA1

Other Studies

1 other study available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Basal Ganglia Diseases

ArticleYear
Chronic treatment with a classical neuroleptic alters excitatory amino acid and GABAergic neurotransmission in specific regions of the rat brain.
    Neuroscience, 1994, Volume: 63, Issue:4

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Autoradiogr

1994